Published in
Elsevier, Lung Cancer, (150), p. 62-69, 2020
DOI: 10.1016/j.lungcan.2020.09.018
Links
Tools
Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL)
Journal article published in 2020 by
Rosario Garcia-Campelo,
Oscar Arrieta,
Bartomeu Massuti,
Delvys Rodriguez-Abreu,
Ana Laura Ortega Granados 
,
Margarita Majem,
David Vicente,
Pilar Lianes,
Joaquim Bosch-Barrera,
Amelia Insa ,
Manuel Dómine,
Noemí Reguart,
María Guirado,
María Ángeles Sala,
Sergio Vázquez-Estevez
and other authors.
,
Margarita Majem,
David Vicente,
Pilar Lianes,
Joaquim Bosch-Barrera,
Amelia Insa ,
Manuel Dómine,
Noemí Reguart,
María Guirado,
María Ángeles Sala,
Sergio Vázquez-Estevez
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 